Quest Diagnostics (DGX) Hits A 52-Week High: What's Driving The Stock?
Zacks Investment Research | Jan 29, 2020 07:52AM ET
On Jan 28, shares of Quest Diagnostics (NYSE:DGX) scaled a new 52-week high of $110.99, closing the session marginally lower at $110.82. In fact, the stock has rallied nearly 10.5% since its third-quarter earnings announcement on Oct 22, 2019.
Expanded long-term partnership with UnitedHealthcare, robust performance by the diagnostic information services wing and impressive full-year guidance have prompted the rally.
Let’s take a closer look at what's working in favor.
Q4 Revenues Likely to be Strong
Despite PAMA reimbursement pressure weighing on the diagnostic testing industry, in the fourth quarter, the company is expected to have fulfilled all five elements of its growth acceleration strategy, just like in the last few quarters. Investors seem to be optimistic about this momentum getting reflected in the upcoming quarterly results, scheduled to be released on Jan 30.
In this regard, in the to-be-reported quarter, the company acquired Clinical Laboratory Services of Boston Clinical Laboratories in Massachusetts, NJ. This transaction is expected to prove immediately accretive to the top line.
Revenues for 2019 were earlier estimated at $7.72 billion. This indicates 2.5% growth from the year-ago reported figure.
Other Encouraging Factors
In January 2020, Quest Diagnostics acquired select assets of Memorial Hermann Health System to broaden its line of diagnostic services. Around the same time, the company acquired Blueprint Genetics to expand its genetic testing portfolio.
Investors have been optimistic about the company’s prospects since it acquired select assets of the clinical laboratory services business of Boston Clinical Laboratories (“BCL”), a Waltham-based regional provider of laboratory services, last December.
Meanwhile, Quest Diagnostics has been having a great run on the bourses in the past year. The stock has rallied 28.6% against the broader Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.